301281.SHE Shandong Keyuan Pharmaceutical Co. Ltd. A
- Market cap
- CNY 4.25B
- P/E
- 57.7x
- P/B
- 2.79x
- ROE
- 7.8%
- Dividend yield
- 0.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301281.SHE undervalued?
Graham number301281.SHE trades 167.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Keyuan Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Shandong Keyuan Pharmaceutical Co. Ltd. A yet.
Shandong Keyuan Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clarithromycin L-lactate; chlorpheniramine maleate; esmolol hydrochloride; isoproterenol hydrochloride; nicotinamide-tinidazole; am…
Full company profileShandong Keyuan Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Keyuan Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 421M | 443M | 448M | 464M | 398M | 643M |
| Gross Profit | 177M | 181M | 211M | 205M | 213M | 355M |
| Operating Income | 90.1M | 98.6M | 65.7M | 61.6M | 44.6M | 134M |
| EBITDA | - | 132M | 115M | 113M | 68.8M | 131M |
| Net Income | 78.2M | 91.3M | 77.0M | 60.4M | 16.6M | 114M |
| EPS | 0.96 | 1.12 | 0.71 | 0.56 | 0.15 | 1.05 |
| Balance Sheet | ||||||
| Total Assets | 560M | 652M | 1.47B | 1.55B | 1.69B | 1.97B |
| Total Liabilities | 129M | 132M | 139M | 193M | 331M | 507M |
| Shareholders' Equity | 431M | 520M | 1.33B | 1.36B | 1.36B | 1.46B |
| Cash & Short-term Investments | 66.0M | 149M | 325M | 178M | 359M | 166M |
| Cash Flow | ||||||
| Operating Cash Flow | 52.0M | 116M | 37.0M | -60.5M | 43.5M | - |
| Capital Expenditure | 20.2M | 31.1M | 70.1M | 296M | 137M | 86.5M |
| Free Cash Flow | 31.8M | 84.8M | -33.1M | -357M | -93.6M | -5.55M |
| Ratios | ||||||
| ROE | 18.1% | 17.6% | 5.8% | 4.4% | 1.2% | 7.8% |
| ROA | 14.0% | 14.0% | 5.2% | 3.9% | 1.0% | 5.8% |
| Net Profit Margin | 18.6% | 20.6% | 17.2% | 13.0% | 4.2% | 17.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shandong Keyuan Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.58%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 149.9%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 24.8M | 0.23 | 149.9% |
| 2024 | CNY 32.6M | 0.30 | 53.9% |
| 2023 | CNY 30.9M | 0.29 | 40.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 26, 2023.
Who owns Shandong Keyuan Pharmaceutical Co. Ltd. A
- Insiders 57.64%
- Institutions 3.04%
- Public & others 39.31%
- Shares outstanding 108M
- Free float 57.0M
Shandong Keyuan Pharmaceutical Co. Ltd. A company profile
- Company name
- Shandong Keyuan Pharmaceutical Co. Ltd. A
- Ticker
- 301281.SHE
- ISIN
- CNE1000061V8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 650
- Fiscal year end
- December
- Address
- Keyuan Street, Jinan, China, 251601
- Phone
- 86 531 8872 9558
- Website
- keyuanpharm.com
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clarithromycin L-lactate; chlorpheniramine maleate; esmolol hydrochloride; isoproterenol hydrochloride; nicotinamide-tinidazole; aminolevulinate; nisoldipine; qupibutu; propafenone hydrochloride; potassium diclofenac; chlorzoxazone; esomeprazole sodium; palonosetron hydrochloride; idalafeng; piroxicam; phenylephrine; vildagliptin; parecoxib sodium; and ruxolitinib hydrochloride. Shandong Keyuan Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Jinan, China.
Shandong Keyuan Pharmaceutical Co. Ltd. A management
1- Ms. Kun Qin CPAVP & Board Secretary · born 1983